Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CART-19 recurrent or refractory source B cell acute lymphoblastic leukemia, single center of safety and effectiveness, single arm, open label, phase II clinical study

Next Previous
Trial Profile

CART-19 recurrent or refractory source B cell acute lymphoblastic leukemia, single center of safety and effectiveness, single arm, open label, phase II clinical study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-Henan-Huarong-Biotechnology (Primary) ; Cyclophosphamide; Fluorouracil
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top